Results 101 to 110 of about 8,661 (182)

Nirmatrelvir and ritonavir combination against COVID‐19 caused by omicron BA.2.2 in the elderly: A single‐center large observational study

open access: yesImmunity, Inflammation and Disease
Background Since coronavirus 2019 (COVID‐19) swept the world, a variety of novel therapeutic and prevention strategies have been developed, among which nirmatrelvir–ritonavir is highly recommended.
Can Chen   +7 more
doaj   +1 more source

A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments [PDF]

open access: yes
Objective: Unusual clinical course Background: SARS-CoV-2 infection can persist in immunocompromised patients with hematological malignancies, despite antiviral treatment.
Cingolani, Antonella   +8 more
core   +1 more source

Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA [PDF]

open access: yes
In the fall of 2023, the US Food and Drug Administration (FDA) authorised the use of the updated Moderna (Sept 11), Pfizer-BioNTech (Sept 11), and Novavax (Oct 3) COVID-19 vaccines containing a monovalent component of the XBB.1.5 variant “to provide ...
Duggal, Abhijit   +4 more
core   +2 more sources

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV) [PDF]

open access: yes
Background Effective antiviral drugs prevent hospitalisation and death from COVID-19. Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 clearance estimated from serial viral genome densities quantitated in ...
Ashley, Elizabeth   +25 more
core   +2 more sources

IPNA clinical practice recommendations on care of pediatric patients with pre-existing kidney disease during seasonal outbreak of COVID-19 [PDF]

open access: yes
The coronavirus disease 2019 (COVID-19) pandemic, instigated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has profoundly impacted healthcare infrastructures around the globe.
Admani B.   +37 more
core   +1 more source

Properties of Algerian Medicinal Thyme Compounds: Simulation using SwissADME and SuperPred Servers for the in Silico Study of Pharmacokinetic Parameters and Bioactivity. [PDF]

open access: yes
A large number of medicinal plants are used for the curative and preventive treatment of many diseases. In this article, we are interested in the study of the biological properties of Algerian medicinal thyme compounds using in-silico approaches.
CHEGHIB, Nedjoua   +5 more
core   +1 more source

Nirmatrelvir-ritonavir for COVID-19 [PDF]

open access: yesCanadian Medical Association Journal, 2022
McDonald, Emily G, Lee, Todd C
openaire   +2 more sources

Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients

open access: yesInfection and Drug Resistance
Na Chen,1,2 Xuben Yu,3 Lu Li,1 Ping Yang,1 Rong Dong,1,4 Yizhen Huang,1,5 Xiao Ling,1,6 Qiaoqiao Shentu,1,7 Wenqiao Yu,8 Saiping Jiang1 1Department of Clinical Pharmaceutical, The First Affiliated Hospital of Zhejiang University School of Medicine ...
Chen N   +9 more
doaj  

In Silico Evaluation of Paxlovid’s Pharmacometrics for SARS-CoV-2: A Multiscale Approach [PDF]

open access: yes, 2022
Bartha Ferenc Ágoston   +4 more
core   +1 more source

Efficient in vitro assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains [PDF]

open access: yes
Novel and repurposed antiviral drugs are available for the treatment of coronavirus disease 2019 (COVID-19). However, antiviral combinations may be more potent and lead to faster viral clearance, but the methods for screening antiviral combinations ...
Agyeman, Akosua Adom   +13 more
core  

Home - About - Disclaimer - Privacy